Chinese Journal of Antituberculosis ›› 2023, Vol. 45 ›› Issue (1): 116-122.doi: 10.19982/j.issn.1000-6621.20220292
• Review Article • Previous Articles
Shang Yuanyuan1, Nie Wenjuan1, Huang Hairong2, Chu Naihui1()
Received:
2022-08-03
Online:
2023-01-10
Published:
2022-12-30
Contact:
Chu Naihui
E-mail:dongchu1994@sina.com
Supported by:
CLC Number:
Shang Yuanyuan, Nie Wenjuan, Huang Hairong, Chu Naihui. Research status of drug resistance of antituberculosis drugs bedaquiline and clofazimine[J]. Chinese Journal of Antituberculosis, 2023, 45(1): 116-122. doi: 10.19982/j.issn.1000-6621.20220292
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20220292
药物 | 基因 | 突变基因 |
---|---|---|
贝达喹啉 | atpE | A63P[ |
氯法齐明 | Rv1979c | V351A[ |
氯法齐明 | Rv1453 | res-sacB-hyg-res基因座缺失[ |
贝达喹啉与氯法齐明 | Rv0678 | S53L[ |
贝达喹啉与氯法齐明 | Rv2535c | c158t[ |
[1] | World Health Organization.Global tuberculosis report 2020. Geneva: Word Health Organization, 2020. |
[2] | World Health Organization. Global tuberculosis report 2021. Geneva: Word Health Organization, 2021. |
[3] | World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2019. |
[4] |
Nimmo C, Millard J, van Dorp L, et al. Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis. Lancet Microbe, 2020, 1(4): e165-e174. doi:10.1016/S2666-5247(20)30031-8.
doi: 10.1016/S2666-5247(20)30031-8. |
[5] |
Williams K, Minkowski A, Amoabeng O, et al. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother, 2012, 56(6): 3114-3120. doi:10.1128/AAC.00384-12.2.
doi: 10.1128/AAC.00384-12 pmid: 22470112 |
[6] |
Nunn AJ, Phillips PPJ, Meredith SK, et al. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med, 2019, 380(13): 1201-1213. doi:10.1056/NEJMoa1811867.
doi: 10.1056/NEJMoa1811867. URL |
[7] |
Koul A, Dendouga N, Vergauwen K, et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol, 2007, 3(6): 323-324. doi:10.1038/nchembio884.
doi: 10.1038/nchembio884. pmid: 17496888 |
[8] |
Preiss L, Langer JD, Yildiz Ö, et al. Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline. Sci Adv, 2015, 1(4): e1500106. doi:10.1126/sciadv.1500106.
doi: 10.1126/sciadv.1500106. URL |
[9] |
Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J, 2017, 49(5):1700387. doi:10.1183/13993003.00387-2017.
doi: 10.1183/13993003.00387-2017. URL |
[10] |
Schnippel K, Ndjeka N, Maartens G, et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med, 2018, 6(9): 699-706. doi:10.1016/S2213-2600(18)30235-2.
doi: 10.1016/S2213-2600(18)30235-2 pmid: 30001994 |
[11] |
Honeyborne I, Lipman M, Zumla A, et al. The changing treatment landscape for MDR/XDR-TB-Can current clinical trials revolutionise and inform a brave new world? Int J Infect Dis, 2019, 80S: S23-S28. doi:10.1016/j.ijid.2019.02.006.
doi: 10.1016/j.ijid.2019.02.006. |
[12] |
Akkerman O, Aleksa A, Alffenaar JW, et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. Int J Infect Dis, 2019, 83: 72-76. doi:10.1016/j.ijid.2019.03.036.
doi: S1201-9712(19)30165-1 pmid: 30953827 |
[13] |
Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med, 2010, 182(5): 684-692. doi:10.1164/rccm.201001-0077OC.
doi: 10.1164/rccm.201001-0077OC. URL |
[14] |
Duan H, Chen X, Li Z, et al. Clofazimine improves clinical outcomes in multidrug-resistant tuberculosis: a randomized controlled trial. Clin Microbiol Infect, 2019, 25(2): 190-195. doi:10.1016/j.cmi.2018.07.012.
doi: 10.1016/j.cmi.2018.07.012. |
[15] |
Tang S, Yao L, Hao X, et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis, 2015, 60(9): 1361-1367. doi:10.1093/cid/civ027.
doi: 10.1093/cid/civ027 pmid: 25605283 |
[16] |
Lamprecht DA, Finin PM, Rahman MA, et al. Turning the respiratory flexibility of Mycobacterium tuberculosis against itself. Nat Commun, 2016, 7: 12393. doi:10.1038/ncomms12393.
doi: 10.1038/ncomms12393 pmid: 27506290 |
[17] |
Yano T, Kassovska-Bratinova S, Teh JS, et al. Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem, 2011, 286(12): 10276-10287. doi:10.1074/jbc.M110.200501.
doi: 10.1074/jbc.M110.200501 pmid: 21193400 |
[18] |
Mirnejad R, Asadi A, Khoshnood S, et al. Clofazimine: A useful antibiotic for drug-resistant tuberculosis. Biomed Pharmacother, 2018, 105: 1353-1359. doi:10.1016/j.biopha.2018.06.023.
doi: S0753-3322(18)32560-5 pmid: 30021373 |
[19] |
Zhang S, Chen J, Cui P, et al. Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis. J Antimicrob Chemother, 2015, 70(9): 2507-2510. doi:10.1093/jac/dkv150.
doi: 10.1093/jac/dkv150 pmid: 26045528 |
[20] |
Zheng H, He W, Jiao W, et al. Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China. BMC Infect Dis, 2021, 21(1): 330. doi:10.1186/s12879-021-06024-8.
doi: 10.1186/s12879-021-06024-8 pmid: 33832459 |
[21] |
Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005, 307(5707): 223-227. doi:10.1126/science.1106753.
doi: 10.1126/science.1106753. pmid: 15591164 |
[22] |
Huitric E, Verhasselt P, Koul A, et al. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother, 2010, 54(3): 1022-1028. doi:10.1128/AAC.01611-09.
doi: 10.1128/AAC.01611-09 pmid: 20038615 |
[23] |
Liu Y, Gao J, Du J, et al. Acquisition of clofazimine resis-tance following bedaquiline treatment for multidrug-resistant tuberculosis. Int J Infect Dis, 2021, 102: 392-396. doi:10.1016/j.ijid.2020.10.081.
doi: 10.1016/j.ijid.2020.10.081. URL |
[24] |
Xu J, Wang B, Hu M, et al. Primary Clofazimine and Beda-quiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother, 2017, 61(6): e00239-17. doi:10.1128/AAC.00239-17.
doi: 10.1128/AAC.00239-17. |
[25] |
Ismail NA, Omar SV, Joseph L, et al. Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study. EBioMedicine, 2018, 28: 136-142. doi:10.1016/j.ebiom.2018.01.005.
doi: S2352-3964(18)30005-7 pmid: 29337135 |
[26] |
Zimenkov DV, Nosova EY, Kulagina EV, et al. Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region. J Antimicrob Chemother, 2017, 72(7): 1901-1906. doi:10.1093/jac/dkx094.
doi: 10.1093/jac/dkx094 pmid: 28387862 |
[27] |
Migliori GB, Falzon D, Marks GB, et al. Commemorating World Tuberculosis Day 2022: recent ERJ articles of critical relevance to ending TB and saving lives. Eur Respir J, 2022, 59(3): 2200149. doi:10.1183/13993003.00149-2022.
doi: 10.1183/13993003.00149-2022. URL |
[28] |
Centers for Disease Control and Prevention. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR Recomm Rep, 2013, 62(RR-09): 1-12.
pmid: 24157696 |
[29] |
Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med, 2014, 371(8): 723-732. doi:10.1056/NEJMoa1313865.
doi: 10.1056/NEJMoa1313865. URL |
[30] |
Pontali E, Sotgiu G, D’Ambrosio L, et al. Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J, 2016, 47(2): 394-402. doi:10.1183/13993003.01891-2015.
doi: 10.1183/13993003.01891-2015 pmid: 26828052 |
[31] |
Ghodousi A, Rizvi AH, Baloch AQ, et al. Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan. Antimicrob Agents Chemother, 2019, 63(9): e00915-19. doi:10.1128/AAC.00915-19.
doi: 10.1128/AAC.00915-19. |
[32] |
Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2014, 58(5): 2979-2981. doi:10.1128/AAC.00037-14.
doi: 10.1128/AAC.00037-14 pmid: 24590481 |
[33] |
Almeida D, Ioerger T, Tyagi S, et al. Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2016, 60(8): 4590-4599. doi:10.1128/AAC.00753-16.
doi: 10.1128/AAC.00753-16 pmid: 27185800 |
[34] |
Loeb LA, Wallace DC, Martin GM. The mitochondrial theory of aging and its relationship to reactive oxygen species damage and somatic mtDNA mutations. Proc Natl Acad Sci U S A, 2005, 102(52): 18769-18770. doi:10.1073/pnas.0509776102.
doi: 10.1073/pnas.0509776102. pmid: 16365283 |
[35] |
Van Rie A, Warren R, Richardson M, et al. Classification of drug-resistant tuberculosis in an epidemic area. Lancet, 2000, 356(9223): 22-25. doi:10.1016/S0140-6736(00)02429-6.
doi: 10.1016/S0140-6736(00)02429-6. pmid: 10892760 |
[36] |
Field SK. Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment? Ther Adv Chronic Dis, 2015, 6(4):170-184. doi:10.1177/2040622315582325.
doi: 10.1177/2040622315582325 pmid: 26137207 |
[37] |
Petrella S, Cambau E, Chauffour A, et al. Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob Agents Chemother, 2006, 50(8): 2853-2856. doi:10.1128/AAC.00244-06.
doi: 10.1128/AAC.00244-06. pmid: 16870785 |
[38] |
Ismail N, Rivière E, Limberis J, et al. Genetic variants and their association with phenotypic resistance to bedaquiline in Mycobacterium tuberculosis: a systematic review and individual isolate data analysis. Lancet Microbe, 2021, 2(11): e604-e616.doi:10.1016/s2666-5247(21)00175-0.
doi: 10.1016/s2666-5247(21)00175-0. |
[39] |
Pang Y, Zong Z, Huo F, et al. In Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China. Antimicrob Agents Chemother, 2017, 61(10): e00900-17. doi:10.1128/AAC.00900-17.
doi: 10.1128/AAC.00900-17. |
[40] |
Phelan J, Coll F, McNerney R, et al. Mycobacterium tuberculosis whole genome sequencing and protein structure modelling provides insights into anti-tuberculosis drug resistance. BMC Med, 2016, 14: 31. doi:10.1186/s12916-016-0575-9.
doi: 10.1186/s12916-016-0575-9 pmid: 27005572 |
[41] |
Li Y, Fu L, Zhang W, et al. The Transcription Factor Rv1453 Regulates the Expression of qor and Confers Resistant to Clofazimine in Mycobacterium tuberculosis. Infect Drug Resist, 2021, 14: 3937-3948. doi:10.2147/IDR.S324043.
doi: 10.2147/IDR.S324043. URL |
[42] |
Ismail NA, Omar SV, Moultrie H, et al. Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. Lancet Infect Dis, 2022, 22(4): 496-506. doi:10.1016/S1473-3099(21)00470-9.
doi: 10.1016/S1473-3099(21)00470-9. URL |
[43] |
Milano A, Pasca MR, Provvedi R, et al. Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL 5 efflux system. Tuberculosis (Edinb), 2009, 89(1): 84-90. doi:10.1016/j.tube.2008.08.003.
doi: 10.1016/j.tube.2008.08.003. URL |
[44] |
Wells RM, Jones CM, Xi Z, et al. Discovery of a siderophore export system essential for virulence of Mycobacterium tuberculosis. PLoS Pathog, 2013, 9(1): e1003120. doi:10.1371/journal.ppat.1003120.
doi: 10.1371/journal.ppat.1003120. |
[45] |
Fang Z, Sampson SL, Warren RM, et al. Iron acquisition strategies in mycobacteria. Tuberculosis (Edinb), 2015, 95(2): 123-130. doi:10.1016/j.tube.2015.01.004.
doi: 10.1016/j.tube.2015.01.004. URL |
[46] |
Villellas C, Coeck N, Meehan CJ, et al. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaqui-line. J Antimicrob Chemother, 2017, 72(3): 684-690. doi:10.1093/jac/dkw502.
doi: 10.1093/jac/dkw502 pmid: 28031270 |
[47] |
Andries K, Villellas C, Coeck N, et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One, 2014, 9(7): e102135. doi:10.1371/journal.pone.0102135.
doi: 10.1371/journal.pone.0102135. |
[48] |
Gupta S, Tyagi S, Bishai WR. Verapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model. Antimicrob Agents Chemother, 2015, 59(1): 673-676. doi:10.1128/AAC.04019-14.
doi: 10.1128/AAC.04019-14. URL |
[49] |
Kadura S, King N, Nakhoul M, et al. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid. J Antimicrob Chemother, 2020, 75(8): 2031-2043. doi:10.1093/jac/dkaa136.
doi: 10.1093/jac/dkaa136 pmid: 32361756 |
[50] |
D’Ambrosio L, Tadolini M, Dupasquier S, et al. ERS/WHO tuberculosis consilium: reporting of the initial 10 cases. Eur Respir J, 2014, 43(1): 286-289. doi:10.1183/09031936.00125813.
doi: 10.1183/09031936.00125813 pmid: 24072213 |
[51] |
Ioerger TR, Feng Y, Chen X, et al. The non-clonality of drug resistance in Beijing-genotype isolates of Mycobacterium tuberculosis from the Western Cape of South Africa. BMC Geno-mics, 2010, 11: 670. doi:10.1186/1471-2164-11-670.
doi: 10.1186/1471-2164-11-670. |
[52] |
Richard M, Gutiérrez AV, Viljoen A, et al. Mutations in the MAB_2299c TetR Regulator Confer Cross-Resistance to Clofazimine and Bedaquiline in Mycobacterium abscessus. Antimicrob Agents Chemother, 2019, 63(1): e01316-18. doi:10.1128/AAC.01316-18.
doi: 10.1128/AAC.01316-18. |
[53] |
Alexander DC, Vasireddy R, Vasireddy S, et al. Emergence of mmpT 5 Variants during Bedaquiline Treatment of Mycobacterium intracellulare Lung Disease. J Clin Microbiol, 2017, 55(2): 574-584. doi:10.1128/JCM.02087-16.
doi: 10.1128/JCM.02087-16 pmid: 27927925 |
[54] |
Bloemberg GV, Keller PM, Stucki D, et al. Acquired Resis-tance to Bedaquiline and Delamanid in Therapy for Tuberculosis. N Engl J Med, 2015, 373(20):1986-1988. doi:10.1056/NEJMc1505196.
doi: 10.1056/NEJMc1505196. URL |
[55] |
de Steenwinkel JE, de Knegt GJ, ten Kate MT, et al. Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. J Antimicrob Chemother, 2010, 65(12): 2582-2589. doi:10.1093/jac/dkq374.
doi: 10.1093/jac/dkq374 pmid: 20947621 |
[56] |
Maartens G, Brill MJE, Pandie M, et al. Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis. Int J Tuberc Lung Dis, 2018, 22(1): 26-29. doi:10.5588/ijtld.17.0615.
doi: 10.5588/ijtld.17.0615 pmid: 29145924 |
[57] |
Gour A, Dogra A, Sharma S, et al. Effect of Disease State on the Pharmacokinetics of Bedaquiline in Renal-Impaired and Diabetic Rats. ACS Omega, 2021, 6(10): 6934-6941. doi:10.1021/acsomega.0c06165.
doi: 10.1021/acsomega.0c06165 pmid: 33748607 |
[58] |
Alghamdi WA, Al-Shaer MH, Kipiani M, et al. Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis. J Antimicrob Chemother, 2021, 76(4): 1019-1024. doi:10.1093/jac/dkaa550.
doi: 10.1093/jac/dkaa550 pmid: 33378452 |
[59] |
Haas DW, Abdelwahab MT, van Beek SW, et al. Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa. J Infect Dis, 226(1): 147-156. doi:10.1093/infdis/jiac024.
doi: 10.1093/infdis/jiac024. URL |
[60] |
Rivera B, Castellsagué E, Bah I, et al. Biallelic NTHL1 Mutations in a Woman with Multiple Primary Tumors. N Engl J Med, 2015, 373(20): 1985-1986. doi:10.1056/NEJMc1506878.
doi: 10.1056/NEJMc1506878. URL |
[61] |
de Vos M, Ley SD, Wiggins KB, et al. Bedaquiline Microhete-roresistance after Cessation of Tuberculosis Treatment. N Engl J Med, 2019, 380(22): 2178-2180. doi:10.1056/NEJMc1815121.
doi: 10.1056/NEJMc1815121. URL |
[62] |
Li J, Yang G, Cai Q, et al. Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis. Int J Infect Dis, 2021, 110: 179-186. doi:10.1016/j.ijid.2021.07.038.
doi: 10.1016/j.ijid.2021.07.038 pmid: 34293490 |
[63] |
Svensson EM, Karlsson MO. Modelling of mycobacterial load reveals bedaquiline’s exposure-response relationship in patients with drug-resistant TB. J Antimicrob Chemother, 2017, 72(12): 3398-3405. doi:10.1093/jac/dkx317.
doi: 10.1093/jac/dkx317 pmid: 28961790 |
[64] |
Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis, 2016, 63(7): e147-e195. doi:10.1093/cid/ciw376.
doi: 10.1093/cid/ciw376. |
[1] | Wang Qian, Wang Jia, Li Yuhong, Liu Eryong, Zhou Lin. Attach importance to childhood tuberculosis and care for children’s health [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 1-5. |
[2] | He Xiaomou, Luo Hui, Ma Jinbao, Ren Fei, Zhao Ali, Yuan Rong. Effect of “trinity” care service on the multidrug-/rifampicin-resistant tuberculosis patients in the intensive phase [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 104-110. |
[3] | Tao Liying, Xu Zheng, Zhao Xin, Li Yanyuan, Li Yamin, Xu Yan, Zhang Yanan, Gao Zhidong. Analysis of tuberculosis screening results among freshmen of high schools and below in Beijing,2021 [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 111-115. |
[4] | Wang Zeming, Shen Adong. Interpretation of the standard of Detection and preventive treatment of latent tuberculosis infection in children [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 13-17. |
[5] | Wang Zeming, Shen Adong. Interpretation of Social Organization Standard of Diagnosis of central nervous system tuberculosis in children [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 18-24. |
[6] | Han Tingting, Liu Guizhen, Chen Qiuqi, Deng Guofang. Interpretation of Framework for collaborative action on tuberculosis and comorbidities [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 25-30. |
[7] | Li Guilian, Fang Min, Jiang Jingwei, Wang Ruihuan, Qian Chengyu, Yu Jinjie, Cao Bin, Xu Da, Zhao Xiuqin, Li Machao, Liu Haican, Sun Lin, Zhu Yu, Wan Kanglin. Exploration for improving the culture-positive rate of Mycobacterium tuberculosis in gastric fluid specimens from pediatric patients with pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 31-37. |
[8] | Li Xiang, Fu Xuwen, Xu Yanling, Gan Wei, Qi Min, Huang Ying. The value of CT signs combined with peripheral blood eosinophils in differentiating pleuropulmonary paragonimiasis from pleural tuberculosis in children [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 38-44. |
[9] | Ren Fei, Ma Jinbao, Li Rong, Yang Han, Yang Hong, Wu Yanqin, Yang Xinjun, Dang Liyun. Efficacy and eligibility of high-dose moxifloxacin short-course regimen for rifampicin-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 52-59. |
[10] | Fan Lichao, Jiao Weiwei, Wu Haoyu, Shen Adong, Chen Yu. Interpretation of WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 6-12. |
[11] | Yu Meiling, Zhang Chenchen, Wei Wenjing, Zhao Yuchuan, Zhuo Wenji, Zheng Lei. Study on high-concentration p-aminosalicylic acid resistant Mycobacterium tuberculosis induced in vitro and the mutation sites [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 60-66. |
[12] | Sheng Yunfeng, Qiu Meihua, Chen Yuanyuan, Sun Lifang, Zhen Libo. Research on mechanisms of dendritic cell miR-17 regulating naive CD4+T lymphocytes unevenly differentiating to Treg/Th17 [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 67-72. |
[13] | Wei Shuzhen, Zhao Yong, Lin Jian, Lin Shufang, Dai Zhisong. Analysis of genotype characteristics and drug resistance of Mycobacterium tuberculosis isolates in Fujian Province from 2017 to 2019 [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 73-78. |
[14] | Xu Yinjuan, Zhao Guolian, Cui Xiaoli, Dang Liyun, Kang Lei, Zhou Yong. The application value of SAT-TB in monitoring the curative effect of patients with tracheobronchial tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 79-84. |
[15] | Zhou Fangjing, Feng Huiying, Fang Lanjun, Chen Yuhui, Wen Wenpei, Liao Qinghua, Wu Huizhong. Analysis on the trend and influencing factors of detection delay in patients with active tuberculosis in Guangdong Province from 2016 to 2020 [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 85-95. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||